Initial Statement of Beneficial Ownership (Form 3)

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Yao Yun 2. Date of Event Requiring Statement (Month/Day/Year) 03/23/2026 3. Issuer Name and Ticker or Trading Symbol Indaptus Therapeutics, Inc. [INDP] (Last) (First) (Middle) C/O INDAPTUS THERAPEUTICS, INC, 3 COLUMBUS CIRCLE, 15TH FLOOR 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) 5. If Amendment, Date Original Filed (Month/Day/Year) (Street) NEW YORK, NY 10019 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Common Stock 41,991,000(1) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Yao Yun C/O INDAPTUS THERAPEUTICS, INC 3 COLUMBUS CIRCLE, 15TH FLOOR NEW YORK, NY 10019		X

Signatures

/s/ Yun Yao		04/02/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	On March 19, 2026, Yun Yao (the "Reporting Person"), the other purchasers and David Elliot Lazar (the "Seller") entered into a securities purchase agreement pursuant to which the Reporting Person acquired 196,800 shares of Series AA Convertible Non-Redeemable Preferred Stock and 253,700 shares of Series AAA Convertible Non-Redeemable Preferred Stock (together, the "Preferred Stock"). Each share of Series AA Preferred Stock is convertible into 20 shares of common stock, and each share of Series AAA Preferred Stock is convertible into 150 shares of common stock. Following the closing on March 23, 2026, the Reporting Person converted all Preferred Stock, resulting in the issuance of 41,991,000 shares of common stock (3,936,000 from Series AA and 38,055,000 from Series AAA).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.